BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kileng H, Kjellin M, Akaberi D, Bergfors A, Duberg AS, Wesslén L, Danielsson A, Gangsøy Kristiansen M, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy. Scand J Gastroenterol 2018;53:1347-53. [PMID: 30394152 DOI: 10.1080/00365521.2018.1511824] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Jones CR, Flower BF, Barber E, Simmons B, Cooke GS. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Res 2019;4:132. [PMID: 31754636 DOI: 10.12688/wellcomeopenres.15411.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
2 Kjellin M, Kileng H, Akaberi D, Palanisamy N, Duberg AS, Danielsson A, Kristiansen MG, Nöjd J, Aleman S, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway. Scand J Gastroenterol 2019;54:1042-50. [PMID: 31424972 DOI: 10.1080/00365521.2019.1652846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]